Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG1005 in breast cancer with recurrent brain metastases
NCT02048059Phase 2Completed
- Sponsor
- Angiochem Inc.
- Start
- Apr 2014
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel trevatide in breast cancer and brain metastases, sponsored by Angiochem Inc. Primary endpoint: Intracranial Objective Response Rate at 1 year. Started Apr 2014; status: completed.
02
Drugs
paclitaxel trevatide
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT02048059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048059.